**Supplementary Table 1: Multivariable linear regression analysis of the relationship between sociodemographic, health and vaccine-related variables on WT- and BA.1-specific IgG concentrations six months post-third COVID-19 vaccine dose.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Immunogenicity outcome**a | **Variable** | **SARS-CoV-2 Variant** | | | | | |
| **Wild-type** | | | **Omicron BA.1** | | |
| **Estimate** | **95% CI** | **p-value** | **Estimate** | **95% CI** | **p-value** |
| **Anti-RBD IgG (log10BAU/ml)** | HIV infection | 0.14 | -0.12 to 0.39 | 0.29 | 0.23 | -0.019 to 0.49 | 0.069 |
| **6 months post-third dose** | Age (per year) | 0.0021 | -0.0042 to 0.0084 | 0.5 | 0.0018 | -0.0044 to 0.0081 | 0.56 |
|  | Male sex | -0.21 | -0.43 to 0.0083 | 0.059 | -0.28 | -0.5 to -0.064 | **0.012** |
|  | White ethnicity | -0.092 | -0.29 to 0.1 | 0.35 | 0.0022 | -0.19 to 0.2 | 0.98 |
|  | # Chronic conditions (per additional) | -0.14 | -0.26 to -0.015 | **0.028** | -0.15 | -0.27 to -0.029 | **0.016** |
|  | Dual ChAdOx1 as initial regimen | -0.089 | -0.42 to 0.24 | 0.59 | -0.16 | -0.49 to 0.17 | 0.33 |
|  | mRNA-1273 as 3rd dose | 0.22 | 0.023 to 0.41 | **0.029** | 0.15 | -0.044 to 0.34 | 0.13 |
|  | Interval btw 2nd and 3rd doses (per day) | 0.0011 | -0.0018 to 0.004 | 0.44 | 0.0015 | -0.0014 to 0.0044 | 0.3 |

aAnalysis was restricted to participants who remained COVID-19 naïve six months post-third vaccine dose

**Supplementary Table 2: Multivariable linear regression analysis of the relationship between sociodemographic, health and vaccine-related variables on WT- and BA.1-specific IgG half-lives following three-dose COVID-19 vaccination.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Immunogenicity outcome**a | **Variable** | **SARS-CoV-2 Variant** | | | | | |
| **Wild-type** | | | **Omicron BA.1** | | |
| **Estimate** | **95% CI** | **p-value** | **Estimate** | **95% CI** | **p-value** |
| **Anti-RBD IgG half-lives** | HIV infection | 1.7 | -25 to 28 | 0.9 | 12 | -18 to 42 | 0.42 |
| **post-3rd dose, in days** | Age (per year) | 0.41 | -0.26 to 1.1 | 0.23 | 0.33 | -0.42 to 1.1 | 0.38 |
|  | Male sex | -21 | -44 to 2.1 | 0.075 | -12 | -39 to 14 | 0.35 |
|  | White ethnicity | 3.9 | -17 to 25 | 0.71 | 6.5 | -17 to 30 | 0.58 |
|  | # Chronic conditions (per additional) | -8.3 | -21 to 4.3 | 0.19 | -9.1 | -23 to 5.1 | 0.21 |
|  | Dual ChAdOx1 as initial regimen | -0.31 | -35 to 35 | 0.99 | -2.7 | -42 to 37 | 0.89 |
|  | mRNA-1273 as 3rd dose | 14 | -6.7 to 34 | 0.18 | -3.9 | -27 to 19 | 0.74 |
|  | Interval btw 2nd and 3rd doses (per day) | 0.011 | -0.3 to 0.32 | 0.94 | -0.066 | -0.41 to 0.28 | 0.7 |

aAnalysis was restricted to participants who remained COVID-19 naïve throughout follow-up, and who completed all three post-third dose study visits

**Supplementary Table 3: Multivariable linear regression analysis of the relationship between sociodemographic, health and vaccine-related variables on WT- and BA.1-specific ACE2 displacement activity six months post-third COVID-19 vaccine dose.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Immunogenicity outcome** | **Variable** | **SARS-CoV-2 Variant** | | | | | |
| **Wild-type** | | | **Omicron BA.1** | | |
| **Estimate** | **95% CI** | **p-value** | **Estimate** | **95% CI** | **p-value** |
| **ACE2 Displacement (%)** | HIV infection | -1.2 | -11 to 9.1 | 0.82 | 11 | -2.6 to 25 | 0.11 |
|  | Age (per year) | -0.068 | -0.32 to 0.19 | 0.6 | -0.23 | -0.57 to 0.11 | 0.19 |
|  | Male sex | -4.3 | -13 to 4.7 | 0.34 | -11 | -23 to 1 | 0.072 |
|  | White ethnicity | 0.68 | -7.2 to 8.6 | 0.86 | -1.1 | -12 to 9.4 | 0.84 |
|  | # Chronic conditions (per additional) | -4.2 | -9 to 0.73 | 0.094 | -4.2 | -11 to 2.3 | 0.2 |
|  | Dual ChAdOx1 as initial regimen | -3.5 | -17 to 10 | 0.61 | 0.53 | -17 to 18 | 0.95 |
|  | mRNA-1273 as 3rd dose | 12 | 4.5 to 20 | **0.0025** | 5 | -5.6 to 16 | 0.35 |
|  | Interval btw 2nd and 3rd doses (per day) | 0.056 | -0.061 to 0.17 | 0.35 | -0.0051 | -0.16 to 0.15 | 0.95 |

aAnalysis was restricted to participants who remained COVID-19 naïve six months post-third vaccine dose

**Supplemental Table 4: Multivariable analyses of the relationship between sociodemographic, health and vaccine-related variables on viral neutralization six months following the third vaccine dose.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Immunogenicity outcomea** | **Variable** | **SARS-CoV-2 Variant** | | | | | |
| **Wild-typec** | | | **Omicron BA.1c** | | |
| **Estimate c** | **95% CI c** | **p-value** | **Odds Ratio c** | **95% CIc** | **p-value** |
| **Log2 viral neutralizationb** | HIV infection | 0.96 | -0.36 to 2.3 | 0.15 | 4.9 | 0.67 to 51 | 0.14 |
|  | Age (per year) | -0.0014 | -0.026 to 0.023 | 0.91 | 0.96 | 0.91 to 1 | **0.045** |
|  | Male sex | -0.52 | -1.3 to 0.27 | 0.2 | 0.28 | 0.052 to 1.2 | 0.1 |
|  | White ethnicity | -0.54 | -1.2 to 0.14 | 0.12 | 1.3 | 0.39 to 4.3 | 0.69 |
|  | # Chronic conditions (per additional) | -0.46 | -0.88 to -0.047 | **0.029** | 0.77 | 0.31 to 1.8 | 0.55 |
|  | Dual ChAdOx1 as initial regimen | 0.72 | -0.46 to 1.9 | 0.23 | 3 | 0.52 to 18 | 0.21 |
|  | mRNA-1273 as 3rd dose | 0.36 | -0.32 to 1 | 0.29 | 0.93 | 0.28 to 3.3 | 0.91 |
|  | Interval btw 2nd and 3rd doses (per day) | -0.0019 | -0.012 to 0.0084 | 0.71 | 0.99 | 0.98 to 1 | 0.55 |
|  | EDTA as anticoagulantd | 0.27 | -1.2 to 1.7 | 0.71 | 0.7 | 0.057 to 7.1 | 0.77 |

aAnalysis was restricted to participants who remained COVID-19 naïve six months post-third vaccine dose

breciprocal plasma dilutions were log2 transformed prior to multivariable analysis.

cMultivariable analysis for wild-type neutralization was performed using linear regression. Multivariable analysis for Omicron BA.1 neutralization was performed using logistic regression due to a high proportion of measurements below the limit of quantification (BLOQ) at this time point.

dNeutralization assays were performed using plasma (not serum as in other analyses), so the models additionally correct for the anticoagulant.